Background: The third-generation EGFR tyrosine kinase inhibitor osimertinib has been approved in many countries to treat advanced NSCLC in patients with the EGFR T790M mutation. As the development of acquired resistance is inevitable, it is urgent that the mechanisms of such resistance be clarified.
Methods: DNA samples from a cohort of 340 patients with lung adenocarcinoma who were taking osimertinib were subjected to next-generation sequencing and screened in terms of the frequencies of the L792H and G796R mutations. Ba/F3 cells stably expressing the EGFR L858R/ T790M mutations (in cis) with either the L792H or G796R mutation were created to investigate the impact of the two novel mutations on EGFR tyrosine kinase inhibitors and other potential drug combinations in vitro. Structural analyses were performed by using Schrödinger/Maestro software (version 11.1.012, Schrödinger LLC, Cambridge, MA).
Results: L792H and G796R were detected in 1.76% (six of 340) and 0.56% (two of 340) patients with lung adenocarcinoma treated with osimertinib, respectively. The introduction of L792H or G796R mutations against an L858R/T790M background caused dramatic reductions in osimertinib sensitivity. Structural modeling showed that mutations in cis with T790M either forced the ligand (osimertinib) to rotate out (breaking the binding) or pulled the hinge loop (breaking the hinge). Various other drug combinations. including cetuximab with EAI045, failed to inhibit either cis mutant effectively.
Conclusions:
The EGFR L858R/T790M/L792H and L858R/ T790M/G796R mutations conferred resistance to osimertinib both in vitro and in silico. For patients in whom the two resistance mutations occur at low frequency, more precise treatment strategies and additional combinational approaches are required.
Introduction
The EGFR T790M gatekeeper mutation in exon 20 develops in 50% to 60% of patients who are resistant to first-generation EGFR tyrosine kinase inhibitors (TKIs). 1 Osimertinib has definitive effects with manageable toxicities on patients with the EGFR T790M mutation who had been pretreated with previously approved EGFR TKIs. The overall response rate ranges from 62% to 70% and the median progression-free survival time ranges from 9.9 to 12.3 months. 2, 3 However, the potential mechanisms of resistance to osimertinib are rather complicated; they include tertiary EGFR mutations and multiple bypass mechanisms. The C797S mutation (with or without T790M) frequently causes osimertinib resistance, and C797S in cis with T790M confers resistance to all current EGFR TKIs in vitro. 4, 5 Apart from C797 changes, other neighboring tertiary mutations such as L792H or G796R have been described, but no in vitro data have as yet confirmed the suspicion that the mutations mediate drug resistance. 6, 7 Methods NGS was performed on a Nextseq 500 platform (Illumina, San Diego, Ca). Mouse Ba/F3 cells stably expressing the EGFR L858R/T790M mutation in cis with either the L792H or G796R mutation were generated as cell models. Schrödinger/Maestro software (version 11.1.012, Schrödinger LLC, Cambridge, MA) was used to analyze the impact of L792H and G796R individually on osimertinib binding. The detailed methods can be found in the Supplementary Materials.
Results

Frequency of L792H and G796R in Patients with Lung Adenocarcinoma
We retrospectively screened a cohort of 340 patients with lung adenocarcinoma treated with osimertinib. Six patients (1.76%) had the L792H mutation and two (0.59%) had the G796R mutation. Furthermore, five of the six patients with the L792H and one with the G796R mutation also had the T790M mutation in cis. In a large population of patients with lung adenocarcinoma (5000 patients) who were not taking osimertinib, L792H and G796R were detected in only one patient each without T790M. The detailed characteristics of the patients in the two cohorts can be found in Table 1 
L858R/T790M/L792H-and L858R/T790M/G796R-Mutant Cells Are Resistant to Osimertinib
We created Ba/F3 cells stably expressing EGFR L858R and T790M mutation in cis with either the L792H or G796R mutation and evaluated the effects of the two tertiary mutations on drug sensitivity. Three approved EGFR TKIs-erlotinib, afatinib, and osimertinib-were tested; none inhibited cell proliferation (Fig. 1A) . Compared with the half maximal inhibitory concentration values for the L858R/T790M double mutant, those for the L858R/T790M/L792H and L858R/T790M/G796R combination mutants for osimertinib increased by about 25-fold and 110-fold when the L792H and G796R mutations were present, respectively (Fig. 1B) . Osimertinib did not inhibit EGFR phosphorylation induced by either triple mutation (Fig. 1C) .
Structural Modeling
We explored the effects of L792H and G796R, each in cis with T790M, on osimertinib binding. The imidazole ring H792 (Fig. 1E ) sterically and energetically hindered the methoxy group of osimertinib. As shown in Figure 1D , the bulky side chain of R796 not only sterically hindered the covalent binding of osimertinib but also rendered binding energetically unfavorable because the hydrophilic groups hindered the hydrophobic region of the drug. R796 faced the solvent, but outward rotation to avoid the hindrance was energetically not favored because the R796 side chain was located in a hydrophobic subpocket formed by Phe795, Pro794, and the greasy core of osimertinib. 
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We screened various drug combinations in an effort to overcome the effects of the two mutations. A combination of the allosteric inhibitors EAI045 and cetuximab overcame the effects of the C797S mutation against an L858R/ T790M background; 8 however, neither L792H nor G796R imparted drug sensitivity to either the combination or Cells expressing various EGFR constructs were treated with drugs at the indicated concentrations for 16 hours and induced with 100 ng/mL of epidermal growth factor for 5 minutes, after which the protein extracts were immunoblotted to detect the indicated proteins. Structural modeling of EGFR G796R (D) and L792H (E) in cis with T790M in a complex with osimertinib. The blue structure represents osimertinib, and the red dashed line indicates steric hindrances created because of the mutual presence of the side chains of mutated residues and the osimertinib core. Both mutations sterically hindered the covalent binding of osimertinib, and the bulky side chain of R796 energetically inhibited such binding because the hydrophilic groups hindered the hydrophobic region of osimertinib. (F and G). Drug screens for the two mutant cell lines. Cells were treated with the indicated concentrations of EGFR tyrosine kinase inhibitors with or without cetuximab (10 mg/mL) (F and G) or with docetaxel alone (H) for 72 hours. In the proliferation experiment, cells were treated with different drugs at the indicated concentrations, and viable cell numbers were measured by using the Celltiter 96 assay 72 hours later. The figures were compared with those for untreated controls (n ¼ 3). The results are expressed as means plus or minus SDs. GI 50, half maximal inhibitory concentration; pEGFR, phospho EGFR protein; CYS, cystine; MET, methionine; GLY, glycine.
EAI045 alone (Fig. 1F and G) . Intriguingly, osimertinib combined with cetuximab reduced the half maximal inhibitory concentration of the L792H mutant from 222 to about 38 nM (see Fig. 1F ). Moreover, a single cytotoxic agent such as docetaxel strongly inhibited the proliferation of cells with both mutations (Fig. 1H ).
L792H and G796R Mutations Coexisting in an Osimertinib-Treated Patient
Stage IV lung adenocarcinoma with brain metastases was diagnosed in a 57-year-old female nonsmoker. Her treatment history and gene profile can be seen in Figure 2A and Supplementary Table 2 . NGS of her cellfree DNA (cfDNA) identified both G796R and L792H in EGFR exon 20; the mutant allele fractions were 2.97% and 1.57%, respectively. Both mutations were in cis with T790M but mutually in trans (Fig. 2B) .
Reported Drug Resistance Mechanisms in Patients with Osimertinib-Treated NSCLC
We searched the MEDLINE and Google Scholar databases using the key terms osimertinib OR AZD9291 and She received erlotinib, 150 mg once daily, and achieved a partial response (PR) (as evaluated by using the Response Evaluation Criteria in Solid Tumors version 1.1 at the 4-week evaluation). Erlotinib was continued as indicated until both the lung and brain disease progressed 27 months later. At that time, we detected both the exon 21 L858R mutation and the exon 20 T790M mutation in rebiopsy tissue samples of the pulmonary lesion. We prescribed four cycles of pemetrexed with carboplatin doublet chemotherapy, followed by two cycles of pemetrexed single-agent maintenance treatment; a PR was attained. However, just 5 months later, both the primary and brain lesions had progressed dramatically once more. We prescribed afatinib, 40 mg once daily, for 9 months; a PR was attained. However, just 5 months later, the primary lesion became enlarged and was accompanied by new brain metastases. We switched the patient to osimertinib, 80 mg daily; PRs of the both primary and metastatic lesions were evident at the 4-week evaluation. Unfortunately, just 7 months later, the brain lesions progressed again. We prescribed several sequential treatments, but all of them failed. The time after each treatment is the progression-free survival time. (B) L792H and G796R are in cis with T790M but in trans with each other in the last plasma sample from this patient (other changes are summarized in Supplementary Table 2) . PC, pemetrexed plus carboplatin; IO, immunotherapeutic pembrolizumab (200 mg every 3 weeks); EþB, erlotinib (150 mg once daily) plus bevacizumab (15 mg/kg every 3 weeks); AþO, afatinib (40 mg daily) plus osimertinib (80 mg daily).
resistance mechanism (Fig. 3A and Supplementary Table 3 ). We found 30 reports on a total of 300 patients. Most non-C797 EGFR tertiary mutations coexisted with other EGFR mutations, such as L792H/F/Y accompanied by C797S/G/N, L718Q, G796S/R, and/or F795C 6,7,9 ( Fig. 3B and C and Supplementary Table 4 ).
Discussion
We measured the frequencies of the L792H and G796R mutations in patients with advanced lung adenocarcinomas and found that the L858R/T790M/L792H and L858R/ T790M/G796R combinations afforded resistance to the third-generation EGFR TKI osimertinib both in vitro and in silico. We also found (in agreement with published reports) that tertiary EGFR mutations, including the two that we have reported here, were relatively rare. However, the annual numbers of patients with newly diagnosed lung cancer in China and the United States are about 733,300 and 22,500, respectively, 10,11 of whom 85% have NSCLC. Among such patients, about 50% of Asians and 10% of whites have EGFR mutations. Such huge numbers of affected patients render even "rare" mutations significant. In addition, the resistance profile of the third-generation EGFR TKI osimertinib is totally different from that of firstand second-generation EGFR TKIs. No predominant gatekeeper resistant gene mutation was seen (not even C797S, the frequency of which was also <20%). The presence of multiple low-frequency mutations and a new resistance profile emphasizes the need for rebiopsy of patients who become drug resistant; NGS is essential in this context.
Both cell proliferation assay and Western blotting showed that the presence of L792H and G796R against a background of EGFR L858R/T790M resulted in significant loss of sensitivity to osimertinib. In addition, structural modeling showed that L792H and G796R dramatically affected osimertinib binding. In the drug screen, all three generations of EGFR TKIs that have been approved as monotherapies failed to kill cells with the two cis mutational patterns. Even a combination of EAI045 and cetuximab exhibited low potency. The number of functional alterations increased when patients received multiple lines of treatment, 12 which might not be overcome by EGFR TKI monotherapy. Therefore, for now, cytotoxic agents appeared to kill all mutational subclones more effectively; docetaxel retained the ability to inhibit mutant cell proliferation in our model. Moreover, considering the poor rate of response to programmed death 1/programmed death ligand 1 checkpoint immunotherapy for EGFR-or ALKpositive patients, 13 the only available treatment option for patients with the cis mutational patterns described earlier in this article may be chemotherapy. Our patients with both L792H and G796R mutations did not respond to any therapy; it is difficult to overcome the effects of the cis mutants. However, if C797 changes are in trans with T790M, first-generation EGFR TKIs are clinically effective. 14, 15 Although trans combinations of C797 and the two new mutations are relatively rare, 16 the behaviors of G796R and L792H mutations in trans with the T790M mutation require further exploration.
Our study had certain limitations. First, as cetuximab exhibits several anticancer mechanisms, in vivo studies are needed to explore and confirm the effects of combining osimertinib with cetuximab in the L858R/ T790M/L792H-mutant pattern. Second, the resistance mechanisms of osimertinib that we summarize were derived mostly from case reports and preliminary reports. Given such publication bias, more analyses are required. Third, for limited plasma samples, we did not confirm the results of cfDNA testing with an orthogonal technique.
In summary, we have identified two novel mutations, G796R and L792H, that in cis with T790M, conferred resistance to the third-generation EGFR TKI osimertinib both in vitro and in silico. Given the complexity of osimertinib resistance and the high level of patient heterogeneity, detailed individualized treatment strategies targeting specific resistance mechanisms are required.
